In all, these results indicated that FGF9 offered considerable benefit for the tumor-promoting ability of CAFs, and miR-214 inhibited the tumor-promoting ability of CAFs possibly by directly reducing FGF9 expression. The gene discussed is FGF9; the disease is neoplasm.